American Association for Cancer Research Inaugurates New Leadership During AACR Annual Meeting 2026
Keith T. Flaherty, MD, FAACR, begins term as AACR President SAN DIEGO – The members of the American Association...
Search/Filter
Loading...
American Association for Cancer Research Recognizes 2025-2026 Research Grantees
PHILADELPHIA – The American Association for Cancer Research (AACR) is proud to announce its newest class of grant recipients. Since 1993, the AACR...
Distribution of Phase I Lung Cancer Trials May Be Consolidating at Top-performing U.S. Sites
SAN DIEGO – Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly...
BCMA-directed CAR T-cell Therapy May Be Effective Against High-risk Smoldering Multiple Myeloma
All patients were negative for minimal residual disease, and no patients experienced progression to active multiple myeloma during the...
A Machine Learning Model that Uses DNA Methylation Patterns May Help Identify the Origin of Cancers of Unknown Primary
This approach may eventually help guide personalized treatment decisions for patients diagnosed with these cancers SAN DIEGO – A...
A Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy in Lung Cancer Patients
SAN DIEGO – A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to...
AACR Announces Recipients of AACR Trailblazer Cancer Research Grants
AACR’s largest-ever grant program will award 15 early-stage and mid-career investigators with $1 million each over 3 years SAN...
New Antibody-drug Conjugate Shows Clinical Benefit for Advanced Platinum-resistant Ovarian Cancer
The investigational drug led to objective response and disease control in patients with late-stage disease SAN DIEGO – Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced...
Next-generation KRAS G12C Inhibitor Elisrasib Elicited Promising Response Rates in Patients With Advanced Lung Cancer
Responses were seen in patients who were not treated with prior KRAS G12C inhibitors as well as those whose...
Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer
SAN DIEGO – The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in patients with previously treated non-small cell lung cancer (NSCLC)...